For patients with psoriasis receiving biologic therapy, residual inflammation (RI), defined as increased inflammatory markers ...

For patients with genital psoriasis, apremilast improved genital Physician Global Assessment scores, itch, and quality of life with a tolerable safety profile.

Treatment with guselkumab among patients with psoriasis does not contribute to the risk for or progression of liver fibrosis.

Find the best scalp sunscreens for sun protection this year, whether you want a lotion, spray or powder. Shop Elta MD, Coola, ...

Residual inflammation persisted among patients with psoriasis despite optimal disease response to biologic therapies, putting ...

Certain biologic therapies, such as ustekinumab, significantly effect hematological and lipid parameters in patients with psoriasis.

The dosing interval for ixekizumab may be extended in some patients with plaque psoriasis, and switching between biologics ...

New research shows that in patients with psoriasis, even though their skin responds well to treatment with biologics, ...

The primary endpoint was met, with 57% of subjects treated with the therapy achieving clear or almost clear skin.

Roflumilast foam, 0.3% (Zoryve) used once-daily significantly improved itch and other symptoms of plaque psoriasis of the scalp and body, the phase III ARRECTOR trial showed.

Research led by the SKiN Center for Dermatology observed substantial clearance of scalp and body psoriasis and rapid itch ...